SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-061295
Filing Date
2023-07-31
Accepted
2023-07-31 16:15:33
Documents
13
Period of Report
2023-07-25
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea182586-8k_unicycive.htm   iXBRL 8-K 34369
2 LETTER FROM MAYER HOFFMAN MCCANN P.C. DATED JULY 31, 2023 ea182586ex16-1_unicycive.htm EX-16.1 2462
  Complete submission text file 0001213900-23-061295.txt   213120

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE uncy-20230725.xsd EX-101.SCH 3018
4 XBRL LABEL FILE uncy-20230725_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE uncy-20230725_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea182586-8k_unicycive_htm.xml XML 3407
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 231127586
SIC: 2834 Pharmaceutical Preparations